Adalipca 40 mg/0.8 ml Injection belongs to the class of monoclonal TNF (Tumor necrosis factor) inhibitors that help reduce signs and symptoms of autoimmune disorders. It is primarily used in the treatment of rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, plaque psoriasis, and psoriatic arthritis. This medicine is also used in the treatment of Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and uveitis.

Adalipca 40 mg/0.8 ml Injection consists of Adalimumab, which works by inhibiting the TNF-α and TNF-β binding to the cell surface, thereby making the TNF cytokine inactive. This helps reduce inflammation and pain caused by various autoimmune diseases.

Adalipca 40 mg/0.8 ml Injection may cause certain side effects such as nausea, headache, back pain, upper respiratory tract infections, vision problems, dizziness, pale skin, numbness, chest pain, rash, and injection site reactions. Most of these side effects do not require medical attention or resolve over time. However, if these side effects persist for longer, please consult your doctor on priority. Adalipca 40 mg/0.8 ml Injection is a parenteral medicine. It will be administered by a trained healthcare doctor. Hence, do not self-administer. Your physician will decide the dose and duration of the medicine based on the type and severity of the condition.

Adalipca 40 mg/0.8 ml Injection should be avoided if you are allergic to any of its components.  Inform your doctor if you have any history of serious infections, tuberculosis, optimistic infections, cancer, alcoholic hepatitis, hepatitis B virus infection, heart failure, liver, heart, or kidney diseases, or a weak immune system, as it can worsen your health condition. Adalipca 40 mg/0.8 ml Injection may cause dizziness, so drive only if you are alert and focused. Adalipca 40 mg/0.8 ml Injection should not be given to children under two years of age as safety has not been established. Consult the doctor if you are pregnant or breastfeeding.

Adalipca 40 mg/0.8 ml Injection consists of Adalimumab, which belongs to the class of monoclonal TNF (Tumor necrosis factor) inhibitors. It works by inhibiting the TNF-α and TNF-β binding to the cell surface, thereby making the TNF cytokine inactive. This helps reduce inflammation and pain, redness, and inflammation (swelling) caused by various autoimmune diseases.

Adalipca 40 mg/0.8 ml Injection should be avoided if allergic to it or any other components present. Inform your doctor if you have any history of serious infections, tuberculosis, optimistic infections, cancer, alcoholic hepatitis, hepatitis B virus infection, heart failure, liver, heart or kidney diseases, weak immune system, multiple sclerosis (nerve and muscle disease), or diabetes as it can worsen your health condition. Do not take live vaccines while being treated with Adalipca 40 mg/0.8 ml Injection to prevent any serious consequences. Adalipca 40 mg/0.8 ml Injection is not recommended for use in children below two years of age as safety and efficacy are not established. This medicine is not recommended for patients suffering from sepsis as it can worsen the condition.

• It is advised to closely monitor the patient for infections like active tuberculosis during and after the treatment, though the patient gets a negative tuberculin test.
• It is essential to inform your doctor if you have any active viral, bacterial, and fungal infections before starting Adalipca 40 mg/0.8 ml Injection.